Elizabeth M. Bengtson

Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

Thomas S. Lin, Kathleen Donohue, John C. Byrd et al. · Journal of Clinical Oncology · 2010 · 75 citations · Full text

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101.

Thomas S. Lin, Kathleen Donohue, Margaret S. Lucas et al. · Blood · 2007 · 34 citations

Randomized phase 3 study in low‐grade lymphoma comparing maintenance anti‐CD20 antibody with observation after induction therapy: A trial of the ECOG‐ACRIN Cancer Research Group (E1496)

Stefan K. Barta, Hailun Li, Howard S. Höchster et al. · Cancer · 2016 · 32 citations · Full text

Profound autoimmune hemolysis and <scp>E</scp>vans syndrome in two asplenic patients with babesiosis

Joseph J. Shatzel, Kelsey Donohoe, Ngoc‐Quynh Chu et al. · Transfusion · 2014 · 15 citations

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101.

Thomas S. Lin, Kathleen Donohue, John C. Byrd et al. · Blood · 2009 · 14 citations